412 related articles for article (PubMed ID: 27473273)
1. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.
Dai CH; Chen P; Li J; Lan T; Chen YC; Qian H; Chen K; Li MY
Oncotarget; 2016 Oct; 7(40):65157-65170. PubMed ID: 27533083
[TBL] [Abstract][Full Text] [Related]
3. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
4. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
6. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
7. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
8. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
9. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
10. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
11. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
12. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
Fan W; Zhang HL; Wu XM
Ai Zheng; 2005 Apr; 24(4):403-7. PubMed ID: 15820060
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
15. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
16. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
19. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
20. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Wu X; Fan W; Xu S; Zhou Y
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5874-9. PubMed ID: 14676109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]